Marker Therapeutics Inc (MRKR)

[TOB]

With two positive Phase 1 Clinical Trials completed this year, a collaboration to move both into Phase 2, low float, low outstanding shares, and super high institutional ownership for an OTC stock, I agree this should be a $3 to $4 stock right now. Probably higher.

I think we should be a 3 to 4 dollar stock right now. time will tell. -tootalljones

We just need more buyers to notice the potential here and rapid upward trajectory of the stock.

Right now, what's the risk? Both Clinical Trials have reported positive results already. So a clinical trial failure is not even possible at this point. Next stage clinical trials are high probability of starting.

Granted TPIV has had a dramatic rally off of the lows, and TPIV is also consolidating after a parabolic rise, but it's still trading below 2014 highs when the clinical trials were still in progress, and results not yet available. TPIV $7 was the 2014 high. TPIV $16 was the 2013 high (both split adjusted).

Of course there are other hurdles and risks, as with any developmental stage bio-tech. Future price action is unknowable, other buyers and sellers will determine that.